Early Anti-VEGF Isn't Worth Cost in Diabetic Retinopathy

A drug tested on patients with nonproliferative diabetic retinopathy did not improve vision outcomes.

Related Keywords

Netherlands ,Chicago ,Illinois ,United States ,Boston ,Massachusetts ,Dutch ,Samsung Bioepis ,Eli Lilly ,Nimesh Patel ,Lee Jampol ,Allergan ,Midwest Eye Institute In Indianapolis ,Jaeb Center ,Retina Network ,Health Research ,Northwestern University Feinberg School Of Medicine ,Regeneron Pharmaceuticals ,Association For Research ,Boehringer Ingelheim ,Novartis ,Genentech ,Raj Maturi ,Midwest Eye Institute ,Medscape Medical ,Northwestern University Feinberg School ,Mass Eye ,Allegro Ophthalmics ,Dutch Ophthalmic ,Diabetic Retinopathy ,Microvascular Complications Of Diabetes ,Retinal Disease ,Retinopathy ,Proliferative Diabetic Retinopathy ,Diabetic Macular Edema ,Vegf Vascular Endothelial Growth Factor ,Vascular Endothelial Growth Factor ,Ascular Endothelial Growth Factor Vegf ,Macular Edema ,Vision Care And Maintenance ,Bedema ,Eye ,Retina ,Visual Acuity ,Ophthalmic ,Phthalmic Route Of Administration ,